Of course, he opposes martial law and supports

Of course, he opposes martial law and supports the impeachment of the Yoon Suk Yeol, but he doesn't want to see anyone who openly scolds him. In my case, I thought that was too much
1. Kim Min-seok's sudden live broadcast, CBS Kim Hyun-jung's admonition,
2. Seo Young-kyo suddenly got up and shouted at the National Assembly to bow his head,
3. Until Han Deok-soo said that it was so bad, but to put a red card in and take it out so that it felt like a power trip to Choi Sang-mok (I think he did everything he did by appointing both judges of the Constitutional Court)
4. Playing in the Judiciary Committee, saying death penalty! Oh, weapons. Personally, I think this is an exception that requires extreme punishment, but it's still a national misfortune. It's amazing that each lawmaker will laugh and flirt.

Despite all this, martial law is so big that I think we should be patient and solidarity no matter what until we quote impeachment, but you guys are as low as the martial law party, and it was a month where I didn't feel any responsibility as a party.

Why has this country been in a dog-like situation where you have to choose between Yoon Suk Yeol and Lee Jae-myung for years.

8. Nike Adidas Prospecs Cavallo

In addition, the Democratic Party of Korea should change the composition of the Judiciary Committee. Whenever Seo Young-kyo's husky voice is heard, his favorability rises steadily. What kind of impeachment is Chungcheong-rae doing? (Roche (affiliated company Cheugai Pharmaceutical Co., Ltd.) Signing ADC deal again)

==========
Roche, which started 2025 by introducing DLL Target ADC products, has signed a joint research and licensing option deal with Araris Biotech this time through its subsidiary, Chugai Pharmaceutical.

The deal is priced at $780 million, and Upfront is undisclosed.

Araris has linker conjugation technology, AraLinQTM, and under the deal, it will conduct initial research with research funding. After that, development after the exercise of option rights is handled by Cheugai.

The two companies have already signed a joint R&D deal in 2023, and this is the second deal.

============
Cheugai Pharmaceutical was established in 1925 and is located in Tokyo, Japan, and incorporated into Roche in 2002. It has more than 7,500 employees.  

Arais was founded in 2019 and is located in Zurich, Switzerland.

==============
(written by Shim Soo-min, Partners Investment)

Telegram Channel: https://t.me/global_biohealthcare_news

https://www.fiercebiotech.com/biotech/roches-chugai-turns-switzerland-adc-development-deal-potentially-worth-more-780-million